Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2020

View Archived Issues

Neoral approved for acute stage Kawasaki disease in Japan

Privigen approved in Japan for agammaglobulinemia and hypogammaglobulinemia

Modiodal approved in Japan for idiopathic hypersomnia

Revlimid capsules granted additional approval in Japan

Preliminary data presented from phase II study of JR-141 in MPS II

DC-007D shows promise as novel thrombolytic in model of focal embolic stroke

Novel genetically engineered murine model of SCBC

FDA grants IND approval for Veyonda plus doxorubicin in soft tissue sarcomas

Orencia approved for prevention of structural damage of joints in current indication of RA

Incyte patents new hSTING receptor agonists

PD-1 blockade interferes with opioid analgesia

T-cell population is biomarker for beta cell function

PureTech Health and Monash University divulge allopregnanolone prodrugs

GlaxoSmithKline presents new ATF-4 inhibitors

Harbour BioMed completes phase I study of HBM-9161 in healthy Chinese subjects

Sumitomo Dainippon Pharma discovers MEN1/KMT2A interaction inhibitors

Artios Pharma synthesizes DNA polymerase inhibitors

FDA approves Nexletol to lower LDL-C in patients with HeFH or ASCVD

Promising trend on survival observed in phase II trial of adrecizumab for septic shock

Blood vessel caveolae control delivery in the brain

FDA approves Vyepti for preventive treatment of migraine

Studies describe noninvasive means of measuring glucose

Phase III INCREASE study of Tyvaso in PH-ILD meets key endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...